Protein C Inhibitor and Other Components of the Protein C Pathway in Patients with Acute Deep Vein Thrombosis during Heparin Treatment

Summary

The protein C inhibitor (PCI) concentration and other parameters of the protein C pathway were studied in 19 patients with symptomatic acute deep vein thrombosis before and during the first 5 days of heparin treatment. The mean levels of PCI antigen and activity decreased rapidly and significantly during the first day of heparin therapy from 83 and 81% to 60 and 59% of the pooled normal human plasma (p <0.01), respectively, and to 56 and 54% after 5 days of treatment (p <0.01). In contrast, antithrom-bin III decreased progressively 25% during 5 days of heparin treatment. Protein C antigen and activity and total protein S remained unchanged during heparin treatment. Free protein S was decreased before heparin treatment (83%, p <0.05) and increased to normal values after 5 days of treatment. C_4b-binding protein was significantly increased before and during heparin treatment (p <0.01). Activated protein C (APC) complexed to its two major plasma inhibitors, PCI and α₁-antitrypsin (α₁AT) were measured by specific ELISA’s. Before treatment, 18 of the 19 patients studied had increased levels of APC: α₁AT complexes with a mean value of 27 ± 22 ng/ml (range, 6−86 ng/ml) compared to normal values (8 ± 2 ng/ml) and 12 of the patients also had detectable APC:PCI complex levels with a mean value of 11 ±17 ng/ml (range, 5−68 ng/ml). Both APC:inhibitor complexes decreased significantly during heparin treatment.

• References

• 1 Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by throm bin. Biochemistry 1977; 16: 5824-31
• 2 Dahlback B, Stenflo J. Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa. Eur J Biochem 1980; 107: 331-5
• 3 Vehar GA, Davie EW. Preparation and properties of bovine factor VIII. Biochemistry 1980; 19: 401-10
• 4 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52
• 5 Branson H, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulmi-nans in a newborn infant. Lancet 1983; 2: 1165-8
• 6 Estellés A, García-Plaza I, Dasf A, Aznar J, Duart M, Sanz G, Pérez-Requejo JL, España F, Jiménez C, Abeledo G. Severe inherited “homozygous” protein C deficiency in a newborn infant. Thromb Haemostas 1984; 52: 53-6
• 7 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8
• 8 Broekmans AW, Bertina RM, Reinalda-Poot J, Engesser L, Muller HP, Leeuw JA, Michiels JJ, Brommer EJ P, Briët E. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemostas 1985 53. 273-7
• 9 Heeb MJ, España F, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 1989; 73: 446-54
• 10 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983 258. 163-8
• 11 Laurell M, Carlson TH, Stenflo J. Monoclonal antibodies against the heparin-dependent protein C inhibitor suitable for inhibitor purification and assay of inhibitor complexes. Thromb Haemostas 1988; 60: 334-9
• 12 España F, Berrettini M, Griffin JH. Inhibition of fibrinolytic and coagulation factors by human plasma protein C inhibitor. Thromb Res 1989; 55: 369-84
• 13 Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-95
• 14 Suzuki K. Biochemistry and Physiology of protein C inhibitor. In: Witt I. (ed). Protein C. Biochemical and Medical Aspects. Walter de Gruyter; Berlin: 1985: 43-59
• 15 Meijers JC M, Kanters DH A J, Vlooswijk RA A, van Herp HE, Hessing M, Buoma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-7
• 16 Stief TW, Radke KP, Heimburger N. Evidence for identity of PCI and plasminogen activator inhibitor 3. Biol Chem Hoppe-Seyler 1987; 368: 1427-33
• 17 Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akiras M, Yamamota S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. J Biol Chem 1987; 262: 611-6
• 18 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem 1988; 263: 11613-6
• 19 España F, Griffin JH. Determination of functional and antigen protein C inhibitor and its complexes with activated protein C in plasma by ELISA’s. Thromb Res 1989; 55: 671-82
• 20 España F, Gruber A, Kelly AB, Hansom SR, Harker LA, Griffin JH. Complexation of activated protein C (APC) with two physiologic plasma inhibitors. Circulation 1988; 78: 318
• 21 España F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Activated protein C complexes with two physiologic inhibitors: protein C inhibitor and α₁-antitrypsin. Thromb Haemostas 1989; 62: 474
• 22 España F, Vicente V, Tabernero D, Griffin JH. ELISA assays fuior protein C inhibitor (PCI, PAI–3). Heparin-induced decrease in circulating protein C inhibitor. Thromb Haemostas 1989 67. 383
• 23 Heeb MJ, España F, Geiger M, Collen D, Stump DC, Griffin JH. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor–3. J Biol Chem 1987; 262: 15313-6
• 24 España F, Estellés A, Aznar J, Gilabert J. Assay of protein C in human plasma: Comparison of amidolytic, coagulation and immunochemical assays. Thromb Res 1986; 44: 771-82
• 25 Gilabert J, Fernández JA, España F, Aznar J, Estellés A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49: 319-29
• 26 Fernández JA, Estellés A, Gilabert J, España F, Aznar J. Functional and immunologic protein S in normal pregnant women and in full-term newborns. Thromb Haemostas 1989; 61: 474-8
• 27 Laurell CB, McKay EJ. Electroimmuno-assay. In: Colowick SP, Kaplam NO. (eds). Methods in Enzymology, Vol 73, pt. B. Academic Press; Orlando, FL: 1981: 339-69
• 28 Conard J, Lecompte T, Elorellou MH, Cazenave B, Samama M. Antithrombin III in patients treated with subcutaneous or intravenous heparin. Thromb Res 1981; 22: 507-11
• 29 Green PJ. Antithrombin III and subcutaneous heparin. Lancet 1980; 1: 374-5
• 30 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Wilhelmsson S. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-40
• 31 Heeb MJ, Mosher D, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989; 73: 455-61
• 32 Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66: 59-63
• 33 Francis Jr RB, Thomas W. Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemostas 1984; 52: 71-4